The invention relates to neurostimulation systems and, more particularly, to stimulation lead introducers.
Neurostimulation systems may be used to deliver neurostimulation therapy to patients to treat a variety of symptoms or conditions such as chronic pain, tremor, Parkinson's disease, multiple sclerosis, spinal cord injury, cerebral palsy, amyotrophic lateral sclerosis, dystonia, torticollis, epilepsy, incontinence, or gastroparesis. A neurostimulation system delivers neurostimulation therapy in the form of electrical pulses. In general, neurostimulation systems deliver neurostimulation therapy via electrodes on stimulation leads located proximate to the spinal cord, pelvic nerves, or stomach, or within the brain of a patient.
The stimulation leads may include percutaneously implanted leads or surgically implanted leads. Surgically implanted leads are often larger and wider than traditional percutaneously implanted leads. For example, surgically implanted leads may include paddle-shaped leads with surface electrodes. Surgically implanted leads are often desirable because they are less susceptible to migration, include unidirectional electrode arrays, and provide reduced power consumption. Although surgical leads can provide more effective leads, percutaneously implanted leads are often preferred because they are implanted in a less invasive manner.
In general, the invention is directed to techniques for percutaneously introducing a generally flat stimulation lead into a target stimulation site via the epidural region proximate the spine of a patient. A number of electrodes on the stimulation lead, which may be a paddle-like lead, rest at a target stimulation site where the electrodes can provide stimulation therapy to the patient.
The process of introducing the stimulation lead includes the use of a hollow stimulation lead introducer, which comprises an elongated sheath and an elongated dilator. The dilator fits within the sheath and serves to widen a path through the epidural region for the introduction of the sheath, and ultimately the stimulation lead. At least a portion of the stimulation lead introducer has an oblong cross-section, allowing passage of flat stimulation leads such as paddle leads.
The stimulation lead introducer may enter the epidural region proximate the spine of a patient via a guidewire. The stimulation lead introducer provides a path through the epidural region of a patient to a target stimulation site. The stimulation lead travels along the path defined by the lead introducer to reach the target stimulation site where it is positioned to deliver therapy to the patient.
In one embodiment, the invention is directed to a stimulation lead introducer comprising an elongated dilator defining a dilator lumen sized to advance over a guidewire, the dilator having a substantially conical distal tip, wherein at least a portion of the conical distal tip has a substantially oblong cross-section, and an elongated sheath defining a sheath lumen sized to accommodate the dilator or the stimulation lead.
In another embodiment, the invention is directed to a method for introducing a stimulation lead comprising inserting a stimulation lead introducer into an epidural region proximate a spine of a patient via a guidewire, wherein the introducer includes an elongated dilator defining a dilator lumen sized to advance over the guidewire, the dilator having a substantially conical distal tip, wherein at least a portion of the conical distal tip has a substantially oblong cross-section, and an elongated sheath defining a sheath lumen sized to accommodate the dilator or the stimulation lead, withdrawing the dilator from the sheath, and introducing a stimulation lead to a target site within the epidural region via the sheath.
In a further embodiment, the invention is directed to a dilator for widening a path for a stimulation lead to travel through an epidural region proximate a spine of a patient, the dilator having a proximal end and a distal end, wherein the dilator defines a dilator lumen sized to advance over a guidewire, the dilator having a substantially conical distal tip, wherein at least a portion of the conical distal tip has a substantially oblong cross-section.
The invention may provide one or more advantages. For example, the invention permits percutaneous introduction of leads that ordinarily require surgical implantation. In particular, generally flat, or “paddle-like,” leads may be introduced into the epidural region proximate a spine of a patient without the need for surgical intervention. Instead, the dilator and sheath associated with the invention permit introduction of flat leads by less invasive, percutaneous incision, reducing patient trauma and recovery time.
The invention may further provide more customizable components for introducing the stimulation lead. In particular, at least one of the sheath and the dilator may include deformable material, such as polyethylene. The deformable properties of the material allow the dilator to be formed to fit the anatomy of a patient more precisely. In addition, the deformable properties of the stimulation lead introducer may result in less trauma and reduce the possibility of causing a “wet tap.” i.e., a cerebral spinal fluid (CSF) leak. A CSF leak may cause severe headaches or, if the leak is severe, neurological damage.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
Needle 12 has a lumen that may be between approximately 14 gauge and 18 gauge to allow needle 12 to receive stylet 14. In some instances, needle 12 may take the form of a modified Tuohy needle, which has an opening that is angled, e.g., approximately 45 degrees, so that an instrument passing through the needle exits through the needle at an angle. Stylet 14 is sized to fit inside needle 12. Stylet 14 fills the lumen of needle 12 to prevent coring in the tissue of a patient when needle 12 is inserted into the patient.
Guidewire 16 is an elongated, flexible instrument with a cross-sectional width sized to fit within needle 12 upon withdrawal of stylet 14. In some embodiments, guidewire 16 may have an outer diameter of approximately 0.050 inches to approximately 0.100 inches (1.27 mm to 2.54 mm). Guidewire 16 is generally cylindrical, and may be steerable to permit deployment of the guidewire to a desired “target” site within the epidural region. In practice, guidewire 16 may be inserted through needle 12 and steered through the epidural region to the target site for neurostimulation therapy.
Guidewire 16 prepares a path for other medical instruments in kit 10 to traverse. In particular, guidewire 16 provides a path that is clear of obstructions so a stimulation lead introducer, formed by dilator 18 and sheath 20, can reach the target site by advancing over guidewire 16.
Dilator 18 is an elongated, hollow structure that has a dilator proximal end and a dilator distal end. Dilator 18 defines a dilator body 26 with a dilator lumen extending between the dilator proximal end and dilator distal end and sized to advance over guidewire 16. A substantially conical distal tip 28 extends from the distal end of dilator body 18. The conical tip, comprising a proximal portion 21 and distal portion 23, widens a path through the epidural region for dilator body 26 to pass. At least a portion of the dilator 18 has a substantially oblong cross-section, which allows a flat, paddle-like stimulation lead 22 to fit through the widened path.
In one embodiment, the proximal portion 21 of the conical structure 28 has a substantially oblong cross-section, whereas the distal portion 23 has a generally circular cross-section. An opening 24 is provided at distal portion 23. Hence, substantially conical distal tip 28 may taper from an oblong cross-section at proximal portion 21 to a circular cross-section at distal portion 23, and hence a circular opening 24. In addition, the dilator lumen may have a substantially oblong cross-section.
Dilator 18 may be made of an extruded or molded material, e.g., a polymeric material. The material may include a substantially deformable material, such as polyethylene. The deformable properties of the material allow dilator 18 to be formed to fit the anatomy of a patient more accurately. In some cases, a physician may be able to shape or form a portion of the dilator 18, such as distal tip 28, to a desired configuration. To that end, the material in distal tip 28 may be selected to deform and hold a resulting shape. In addition, the deformable properties of the stimulation lead introducer may reduce trauma upon passage within the epidural region and thereby decrease the probability of causing a “wet tap”, or CSF leak, which is an event that may cause severe headaches or, if the leak is severe, may cause neurological damage. A CSF leak may occur if the stimulation lead introducer is inserted too far into the epidural region, causing a puncture in the dura membrane of the epidural region. The deformable properties of the stimulation lead introducer may allow the distal tip 28 to be sufficiently soft so that it deforms enough to prevent puncture and a resulting CSF leak. In particular, distal tip 28 may bend to the side upon reaching the dura membrane, preventing a puncture in the dura membrane.
Sheath 20, an elongated, hollow structure defining an inner sheath lumen, includes a sheath proximal end and a sheath distal end. In one embodiment, the outside of sheath 20 has a substantially oblong cross-section. In another embodiment, the sheath lumen has a substantially oblong cross-section, whereas the outside is substantially circular. Thus, in some embodiments, the entire sheath 20 has an oblong cross-section, while in other embodiments, the sheath outer diameter has a non-oblong cross-section and the inner lumen has an oblong cross-section. The term “oblong,” with respect to dilator 18 and sheath 20, refers generally to a cross-section, taken normal (i.e., perpendicular) to the longitudinal extent of the respective component, with a width that is substantially greater than its height.
Like dilator 18, sheath 20 may be made of extruded or molded material. The material may include a substantially deformable material, such as polyethylene. The deformable properties of the material allow sheath 20 to be formed to fit the anatomy of a patient more accurately. In addition, sheath 20 may include radio-opaque material that is viewable under fluoroscopic imaging to aid medical personnel in visualizing the sheath during percutaneous introduction.
In practice, sheath 20 fits over dilator 18 to form the stimulation lead introducer. In addition, sheath 20 allows for the passage of a stimulation lead when dilator 16 is not present in sheath 20, i.e., upon withdrawal of dilator 16. In one embodiment, sheath 20 may be shorter than dilator 18 so that the conical distal tip 28 of dilator 18 extends beyond the distal end of sheath 20.
Stimulation lead 22 may include a paddle-shaped, flat structure with at least one electrode 29 to provide stimulation to a patient, as shown in
The conical tip 28 of dilator 18, comprising a proximal and distal end, serves to widen a path through the epidural region for the rest of the stimulation lead introducer to pass through. At least a portion of dilator 18 may have an oblong cross-section so a flat, paddle-like stimulation lead 22 can fit in the widened path. In a further embodiment, the dilator lumen has a substantially oblong cross-section. As shown in
In one embodiment, the proximal opening may have a width of approximately 0.175 inches to approximately 0.195 inches (4.45 mm to 4.95 mm), and the distal opening 24 may have a width of approximately 0.055 inches to approximately 0.105 inches (1.27 mm to 2.67 mm). Hence, the proximal width may be greater than approximately three times the distal width. In one embodiment, the dilator body 26 has a height that is greater than the height of distal opening 24. The height and width of dilator 18 may be designed to fit a particular stimulation lead that may be passed through the path created by needle 12 and dilator 18. In one embodiment, dilator 18 may be longer than sheath 20 so the conical structure 28 of dilator 18 extends past the distal end of sheath 20.
Dilator 18 may comprise extruded or molded material. The material may include a deformable material such as a polymer. In particular, the polymer may comprise polyethylene. The deformable properties of the material allow dilator 18 to be formed to better fit the anatomy of a patient.
Sheath 20 may comprise extruded or molded material. The material may include a deformable material such as a polymer. In particular, the polymer may comprise polyethylene. The deformable properties of the material allow dilator 18 to be formed to better fit the anatomy of a patient. In addition, sheath 20 may include radio-opaque material that is viewable under fluoroscopic imaging.
In practice, sheath 20 is part of a stimulation lead introducer that also includes dilator 18. In one embodiment, sheath 20 may be shorter than dilator 18. A substantially conical structure 28 on the distal end of dilator 18 may extend past the distal end of sheath 20. In addition, sheath lumen of sheath 20 allows for the passage of a stimulation lead when dilator 16 is not present within sheath 20.
At least a portion of the stimulation lead introducer has a substantially oblong cross-section. As shown in
At least a portion of the stimulation lead introducer 30 may include deformable material. In particular, sheath 20 or dilator 18 may include a deformable material such as polyethylene. The deformable properties of the material allow sheath 20 to be formed to fit the anatomy of a patient more accurately. In addition, at least a portion of stimulation lead introducer 30 may include a radiopaque material that is viewable under fluoroscopic imaging. In particular, sheath 20 may include the radiopaque material.
In practice, stimulation lead introducer 30 enters the epidural region of a patient by advancing over the guidewire 16, which prepares a path to a target site for stimulation lead introducer 30 to follow. An imaging technique may aid the introduction of the stimulation lead introducer 30. For example, as discussed above, fluoroscopic imaging may be used to follow the progress of stimulation lead introducer 30 as it advances over guidewire 16. The stimulation lead introducer 30 may widen the path to the target site. In particular, stimulation lead introducer 30 may widen the path so that the cross-section of the path is substantially oblong.
After stimulation lead introducer 30 widens the path for stimulation lead 22 to get to the target site, dilator 18 may be withdrawn. Sheath 20 remains in the epidural region, maintaining the path for the introduction of stimulation lead 22. A stimulation lead 22 may be introduced via sheath 20 and may be placed at the target site to deliver stimulation therapy to a patient. In particular, electrodes 29 on stimulation lead 22 may provide therapy by stimulating the target site.
As shown in
After the needle has been properly inserted into the epidural region of a patient, stylet 14 may be withdrawn (42) from needle 12. In one embodiment, a syringe may be used for placing the needle. If a syringe is used, the syringe is attached to needle 12 (46). Using the syringe may confirm that the needle has been properly placed into the epidural region. In particular, the syringe may attempt to inject fluid, such as air, into the epidural region (48). The fluid from the syringe will encounter substantial resistance if the needle is not correctly placed in the epidural region. On the other hand, a lack of substantial resistance to fluid from the syringe may indicate that the needle 12 has been correctly placed in the epidural region. Once needle 12 has been correctly placed, the syringe may be removed.
In any event, needle 12 is placed in the epidural region, regardless of the presence of the syringe. Upon proper placement of needle 12, a guidewire 16 is inserted (50) into the epidural region via the lumen defined by needle 12. In particular, guidewire 16 slides through the lumen defined by needle 12. Guidewire 16 may be maneuvered through the epidural region until it reaches a target site, wherein the target site is the location where a stimulation lead will be placed for providing stimulation therapy to the patient. In one embodiment, an imaging technique may aid the maneuvering of guidewire 16. For example, the imaging technique may include fluoroscopic imaging.
After the guidewire 16 has entered the body of a patient, the needle is withdrawn (52). In one embodiment, the needle is withdrawn after guidewire 16 has reached the target site for therapy. A small incision may be made (54) proximate the spine to allow entry of a stimulation lead introducer 30. A sheath 20 and a dilator 18, collectively the stimulation lead introducer 30, are inserted (56) through the incision. The dilator 18 is disposed coaxially within sheath 20. At least a portion of stimulation lead introducer 30 may have a cross-section that is substantially oblong.
Upon insertion, stimulation lead introducer 30 is advanced over guidewire 16 until it reaches the therapy target site. As described above, the dilator serves to widen a path surrounding guidewire 16 so a stimulation lead can fit through the path. Sheath 20 serves to maintain the path, which may be oblong, that dilator 18 widens. Once the stimulation lead introducer 30 has reached the therapy target site, dilator 18 is withdrawn from sheath 20 (58). At this point, guidewire 16 is withdrawn (60) from sheath 20, leaving a void within sheath 20. The void is filled by a stimulation lead 22. Stimulation lead 22 is inserted through the incision (62) and advances through sheath 20 until it reaches the therapy target site. Once stimulation lead 22 reaches the therapy target site, sheath 20 is withdrawn (64) from the epidural region. Electrodes 29 on stimulation lead 22 are activated (66) to provide therapy to the patient, e.g., by coupling a proximal end of stimulation lead 22 to a neurostimulator. In one embodiment, a lead extension may be provided to couple stimulation lead 22 to the neurostimulator.
Various embodiments of the invention have been described. These and other embodiments are within the scope of the following claims.
This application is a continuation of U.S. utility application Ser. No. 14/562,469, filed Dec. 5, 2014, and issuing as U.S. Pat. No. 9,687,637, which is a continuation of U.S. utility application Ser. No. 13/766,601, filed Feb. 13, 2013 and issued as U.S. Pat. No. 8,909,353, which is a continuation of U.S. utility application Ser. No. 11/823,521, filed Jun. 28, 2007 and issued as U.S. Pat. No. 8,386,052, which is a continuation of U.S. utility application Ser. No. 10/773,121, filed Feb. 5, 2004 and issued as U.S. Pat. No. 8,340,779, which is a continuation-in-part of U.S. utility application Ser. No. 10/718,038, filed Nov. 20, 2003, which claims the benefit of U.S. provisional application No. 60/499,207, filed Aug. 29, 2003, the entire content of each of which is incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3211151 | Foderick et al. | Oct 1965 | A |
3385300 | Holter | May 1968 | A |
3978865 | Trabucco | Sep 1976 | A |
4044774 | Corbin et al. | Aug 1977 | A |
4058128 | Frank et al. | Nov 1977 | A |
4141365 | Fischell et al. | Feb 1979 | A |
4142530 | Wittkampf | Mar 1979 | A |
4143658 | Rambosek et al. | Mar 1979 | A |
4166469 | Littleford | Sep 1979 | A |
4177818 | De Pedro | Dec 1979 | A |
4270549 | Heilman | Jun 1981 | A |
4285347 | Hess | Aug 1981 | A |
4512351 | Pohndorf | Apr 1985 | A |
4545374 | Jacobson | Oct 1985 | A |
4549556 | Tarjan et al. | Oct 1985 | A |
4596559 | Fleischhacker | Jun 1986 | A |
4650472 | Bates | Mar 1987 | A |
4658835 | Pohndorf | Apr 1987 | A |
4660571 | Hess et al. | Apr 1987 | A |
4726373 | Greengrass | Feb 1988 | A |
4735208 | Wyler et al. | Apr 1988 | A |
4744371 | Harris | May 1988 | A |
4759748 | Reed | Jul 1988 | A |
4772266 | Groshong | Sep 1988 | A |
4805625 | Wyler | Feb 1989 | A |
4808157 | Coombs | Feb 1989 | A |
4919653 | Martinez et al. | Apr 1990 | A |
5002053 | Garcia-Rill et al. | Mar 1991 | A |
5031618 | Mullett | Jul 1991 | A |
5156592 | Martin et al. | Oct 1992 | A |
5216045 | Hickner | Jun 1993 | A |
5255691 | Otten | Oct 1993 | A |
5275611 | Behl | Jan 1994 | A |
5300110 | Latterell et al. | Apr 1994 | A |
5342384 | Sugarbaker | Aug 1994 | A |
5397341 | Hirschberg et al. | Mar 1995 | A |
5409469 | Schaerf | Apr 1995 | A |
5443492 | Stokes et al. | Aug 1995 | A |
5454364 | Kruger | Oct 1995 | A |
5458631 | Xavier | Oct 1995 | A |
5496344 | Kanesaka et al. | Mar 1996 | A |
5517846 | Caggiani | May 1996 | A |
5531684 | Ensminger et al. | Jul 1996 | A |
5545207 | Smits et al. | Aug 1996 | A |
5618287 | Fogarty et al. | Apr 1997 | A |
5639276 | Weinstock et al. | Jun 1997 | A |
5662689 | Elsberry et al. | Sep 1997 | A |
5669882 | Pyles | Sep 1997 | A |
5676655 | Howard, III et al. | Oct 1997 | A |
5695470 | Roussigne et al. | Dec 1997 | A |
5713867 | Morris | Feb 1998 | A |
5725504 | Collins | Mar 1998 | A |
5730754 | Obenchain | Mar 1998 | A |
5733316 | Tierney et al. | Mar 1998 | A |
5762629 | Kambin | Jun 1998 | A |
5788713 | Dubach et al. | Aug 1998 | A |
5792187 | Adams | Aug 1998 | A |
5807350 | Diaz | Sep 1998 | A |
5817131 | Elsberry et al. | Oct 1998 | A |
5843146 | Cross, Jr. | Dec 1998 | A |
5846226 | Urmey | Dec 1998 | A |
5868729 | Pelfrey | Feb 1999 | A |
5997508 | Lunn et al. | Dec 1999 | A |
6002964 | Feler et al. | Dec 1999 | A |
6038480 | Hrdlicka et al. | Mar 2000 | A |
6058331 | King | May 2000 | A |
6090072 | Kratoska et al. | Jul 2000 | A |
6104957 | Alo et al. | Aug 2000 | A |
6104960 | Duysens et al. | Aug 2000 | A |
6106540 | White et al. | Aug 2000 | A |
6134470 | Hartlaub | Oct 2000 | A |
6146371 | DeWindt et al. | Nov 2000 | A |
6149657 | Kuzma | Nov 2000 | A |
6161029 | Spreigl et al. | Dec 2000 | A |
6167311 | Rezai | Dec 2000 | A |
6205361 | Kuzma et al. | Mar 2001 | B1 |
6216045 | Black et al. | Apr 2001 | B1 |
6228052 | Pohndorf | May 2001 | B1 |
6236892 | Feler | May 2001 | B1 |
6249707 | Kohnen et al. | Jun 2001 | B1 |
6254598 | Edwards et al. | Jul 2001 | B1 |
6277094 | Schendel | Aug 2001 | B1 |
6277108 | McBroom et al. | Aug 2001 | B1 |
6308103 | Gielen | Oct 2001 | B1 |
6309401 | Redko et al. | Oct 2001 | B1 |
6360750 | Gerber et al. | Mar 2002 | B1 |
6415187 | Kuzma et al. | Jul 2002 | B1 |
6418344 | Rezai et al. | Jul 2002 | B1 |
6466817 | Kaula et al. | Oct 2002 | B1 |
6473653 | Schallhorn et al. | Oct 2002 | B1 |
6478806 | McFarlane | Nov 2002 | B2 |
6494868 | Amar | Dec 2002 | B2 |
6494893 | Dubrul et al. | Dec 2002 | B2 |
6500128 | Marino | Dec 2002 | B2 |
6505075 | Weiner | Jan 2003 | B1 |
6512958 | Swoyer et al. | Jan 2003 | B1 |
6516226 | Bishay et al. | Feb 2003 | B1 |
6517477 | Wendlandt | Feb 2003 | B1 |
6520907 | Foley et al. | Feb 2003 | B1 |
6522927 | Bishay et al. | Feb 2003 | B1 |
6522932 | Kuzma et al. | Feb 2003 | B1 |
6530902 | Jonkman | Mar 2003 | B1 |
6539264 | Bishay et al. | Mar 2003 | B1 |
6542780 | Leonard | Apr 2003 | B1 |
6544270 | Zhang | Apr 2003 | B1 |
6549810 | Leonard et al. | Apr 2003 | B1 |
6553264 | Redko et al. | Apr 2003 | B2 |
6556869 | Leonard et al. | Apr 2003 | B1 |
6560491 | Leonard et al. | May 2003 | B1 |
6564078 | Marino et al. | May 2003 | B1 |
6565521 | Silberg | May 2003 | B1 |
6565594 | Herweck et al. | May 2003 | B1 |
D475463 | Leyde et al. | Jun 2003 | S |
6587733 | Cross, Jr. et al. | Jul 2003 | B1 |
6673091 | Shaffer et al. | Jan 2004 | B1 |
6735475 | Whitehurst et al. | May 2004 | B1 |
6802807 | Anderson et al. | Oct 2004 | B2 |
6836687 | Kelley et al. | Dec 2004 | B2 |
6840899 | Koga et al. | Jan 2005 | B2 |
6847849 | Mamo et al. | Jan 2005 | B2 |
6866044 | Bardy et al. | Mar 2005 | B2 |
6866650 | Stevens et al. | Mar 2005 | B2 |
6971393 | Mamo et al. | Dec 2005 | B1 |
6978180 | Tadlock | Dec 2005 | B2 |
7010345 | Hill et al. | Mar 2006 | B2 |
7092765 | Geske et al. | Aug 2006 | B2 |
7120495 | Bardy et al. | Oct 2006 | B2 |
7792591 | Rooney et al. | Sep 2010 | B2 |
7813803 | Heruth et al. | Oct 2010 | B2 |
7890166 | Heruth et al. | Feb 2011 | B2 |
8204607 | Rooney et al. | Jun 2012 | B2 |
8244360 | Heruth et al. | Aug 2012 | B2 |
8340779 | Harris | Dec 2012 | B2 |
8386052 | Harris | Feb 2013 | B2 |
8588914 | Rooney et al. | Nov 2013 | B2 |
8620435 | Rooney et al. | Dec 2013 | B2 |
8644941 | Rooney et al. | Feb 2014 | B2 |
8909353 | Harris | Dec 2014 | B2 |
9687637 | Harris | Jun 2017 | B2 |
20010049502 | Chen | Dec 2001 | A1 |
20020022873 | Erickson et al. | Feb 2002 | A1 |
20020035377 | Bardy et al. | Mar 2002 | A1 |
20020035378 | Bardy et al. | Mar 2002 | A1 |
20020035381 | Bardy et al. | Mar 2002 | A1 |
20020055675 | Llinas et al. | May 2002 | A1 |
20020072768 | Ginn | Jun 2002 | A1 |
20020103510 | Bardy et al. | Aug 2002 | A1 |
20020107553 | Hill et al. | Aug 2002 | A1 |
20020143369 | Hill et al. | Oct 2002 | A1 |
20020147485 | Mamo et al. | Oct 2002 | A1 |
20020165536 | Kelley et al. | Nov 2002 | A1 |
20020165537 | Kelley et al. | Nov 2002 | A1 |
20020165586 | Hill et al. | Nov 2002 | A1 |
20020198572 | Weiner | Dec 2002 | A1 |
20030004549 | Hill et al. | Jan 2003 | A1 |
20030028146 | Aves | Feb 2003 | A1 |
20030028147 | Aves et al. | Feb 2003 | A1 |
20030028654 | Abjanic et al. | Feb 2003 | A1 |
20030035377 | Ju | Feb 2003 | A1 |
20030036787 | Redko et al. | Feb 2003 | A1 |
20030078633 | Firlik et al. | Apr 2003 | A1 |
20030083688 | Simonson | May 2003 | A1 |
20030114908 | Flach | Jun 2003 | A1 |
20030144709 | Zabara et al. | Jul 2003 | A1 |
20030158545 | Hovda et al. | Aug 2003 | A1 |
20030212445 | Weinberg | Nov 2003 | A1 |
20040015204 | Whitehurst et al. | Jan 2004 | A1 |
20040019359 | Worley et al. | Jan 2004 | A1 |
20040059348 | Geske et al. | Mar 2004 | A1 |
20040111080 | Harper et al. | Jun 2004 | A1 |
20040122477 | Whitehurst et al. | Jun 2004 | A1 |
20040171986 | Tremaglio, Jr. et al. | Sep 2004 | A1 |
20040176830 | Fang | Sep 2004 | A1 |
20040176930 | Spinrad et al. | Sep 2004 | A1 |
20040210245 | Erickson et al. | Oct 2004 | A1 |
20040240245 | Kenny, Jr. et al. | Dec 2004 | A1 |
20040243205 | Keravel et al. | Dec 2004 | A1 |
20050015117 | Gerber | Jan 2005 | A1 |
20050027282 | Schweikert et al. | Feb 2005 | A1 |
20050033393 | Daglow | Feb 2005 | A1 |
20050049542 | Sigg et al. | Mar 2005 | A1 |
20050049663 | Harris et al. | Mar 2005 | A1 |
20050049664 | Harris et al. | Mar 2005 | A1 |
20050070969 | Gerber | Mar 2005 | A1 |
20050085790 | Guest et al. | Apr 2005 | A1 |
20050107861 | Harris et al. | May 2005 | A1 |
20050154437 | Williams | Jul 2005 | A1 |
20050182470 | Cross, Jr. | Aug 2005 | A1 |
20050222628 | Krakousky | Oct 2005 | A1 |
20050246006 | Daniels | Nov 2005 | A1 |
20050256452 | DeMarchi et al. | Nov 2005 | A1 |
20050288758 | Jones et al. | Dec 2005 | A1 |
20050288759 | Jones et al. | Dec 2005 | A1 |
20060025649 | Smith et al. | Feb 2006 | A1 |
20060030899 | O'Keeffe et al. | Feb 2006 | A1 |
20060058575 | Zaddem et al. | Mar 2006 | A1 |
20060122676 | Ko et al. | Jun 2006 | A1 |
20060189940 | Kirsch | Aug 2006 | A1 |
20060217755 | Eversull et al. | Sep 2006 | A1 |
20060270978 | Binmoeller et al. | Nov 2006 | A1 |
20070021801 | Heruth et al. | Jan 2007 | A1 |
20070021802 | Heruth et al. | Jan 2007 | A1 |
20070039625 | Heruth et al. | Feb 2007 | A1 |
20070073353 | Rooney et al. | Mar 2007 | A1 |
20070073356 | Rooney et al. | Mar 2007 | A1 |
20070073357 | Rooney et al. | Mar 2007 | A1 |
20070118196 | Rooney et al. | May 2007 | A1 |
20070150034 | Rooney et al. | Jun 2007 | A1 |
20080009929 | Harris et al. | Jan 2008 | A1 |
20100324570 | Rooney et al. | Dec 2010 | A1 |
Number | Date | Country |
---|---|---|
19758114 | Aug 2001 | DE |
0334116 | Sep 1989 | EP |
0479565 | Apr 1992 | EP |
0655257 | May 1995 | EP |
0792660 | Sep 1997 | EP |
0898481 | Mar 1999 | EP |
0972538 | Jan 2000 | EP |
1048270 | Nov 2000 | EP |
1048271 | Nov 2000 | EP |
1181947 | Feb 2002 | EP |
1360972 | Nov 2003 | EP |
2688407 | Sep 1993 | FR |
2000271225 | Oct 2000 | JP |
WO 8901797 | Mar 1989 | WO |
WO 9528976 | Nov 1995 | WO |
WO 9604040 | Feb 1996 | WO |
WO 9730746 | Aug 1997 | WO |
WO 9737720 | Oct 1997 | WO |
WO 9740880 | Nov 1997 | WO |
WO 9830265 | Jul 1998 | WO |
WO 9930762 | Jun 1999 | WO |
WO 9936113 | Jul 1999 | WO |
WO 9952583 | Oct 1999 | WO |
WO 0076404 | Dec 2000 | WO |
WO 0102047 | Jan 2001 | WO |
WO 0124872 | Apr 2001 | WO |
WO 0158519 | Aug 2001 | WO |
WO 0189626 | Nov 2001 | WO |
WO 0205867 | Jan 2002 | WO |
WO 0234330 | May 2002 | WO |
WO 0236179 | May 2002 | WO |
WO 0237330 | May 2002 | WO |
WO 02068042 | Sep 2002 | WO |
WO 02072192 | Sep 2002 | WO |
WO 02087678 | Nov 2002 | WO |
WO 03011361 | Feb 2003 | WO |
WO 03013650 | Feb 2003 | WO |
WO 03026736 | Apr 2003 | WO |
WO 03047687 | Jun 2003 | WO |
WO 2004009150 | Jan 2004 | WO |
WO 2004012613 | Feb 2004 | WO |
WO 2004012812 | Feb 2004 | WO |
WO 2004060464 | Jul 2004 | WO |
WO 2005016447 | Feb 2005 | WO |
Entry |
---|
“Polyethylene,” Definition from Columbia Electronic Encyclopedia, www.answers.com, defined: polyethylene, retrieved from internet Aug. 31, 2005, 4 pp. |
Kapural et al., “Occipital Nerve Electrical Stimulation via the Midline Approach and Subcutaneous Surgical Leads for Treatment of Severe Occipital Neuralgia:A Pilot Study,” Anesthesia Analgesia, vol. 101, Aug. 2005, pp. 171-174. |
Norman, “Epidural Analgesia Using Loss of Resistance with Air Versus Saline: Does it Make a Difference? Should We Reevaluate Our Practice?,” AANA Journal, vol. 71(6), Dec. 2003, pp. 449-453. |
“Percutaneous Lead Introducer Accessory Kit for Spinal Cord Stimulation (SCS),” Medtronic, Inc., 2001, 2 pp. |
International Search Report and the Written Opinion from Counterpart International Patent Application No. PCT/US2004/026863, dated Nov. 19, 2004, 12 pp. |
International Preliminary Report on Patentability from Counterpart International Patent Application No. PCT/US2004/026863, dated Aug. 8, 2005, 9 pp. |
Summons to Attend Oral Proceedings from Counterpart European Patent Application No. 04781529.5, dated Dec. 1, 2010, 4 pp. |
Response to Summons to Attend Oral Proceedings dated Dec. 1, 2010, from Counterpart European Patent Application No. 04781529.5, dated Mar. 4, 2011, 7 pp. |
Examination Report from Counterpart European Patent Application No. 04781529.5, dated Feb. 17, 2009, 3 pp. |
Response to Examination Report dated Feb. 17, 2009, from Counterpart European Patent Application No. 04781529.5, dated May 5, 2009, 2 pp. |
Examination Report from Counterpart European Patent Application No. 04781529.5, dated Dec. 8, 2009, 4 pp. |
Response to Examination Report dated Dec. 8, 2009, from Counterpart European Patent Application No. 04781529.5, dated Jun. 15, 2010, 14 pp. |
Prosecution History from U.S. Appl. No. 10/718,038, dated Sep. 7, 2005 through Sep. 7, 2005, 7 pp. |
Prosecution History from U.S. Appl. No. 10/773,121, dated Sep. 7, 2005 through May 11, 2012, 165 pp. |
Prosecution History from U.S. Appl. No. 11/823,521, dated Sep. 8, 2009 through Oct. 30, 2012, 127 pp. |
Prosecution History from U.S. Appl. No. 13/766,601, dated Aug. 5, 2013 through Aug. 4, 2014, 54 pp. |
Prosecution History from U.S. Appl. No. 14/562,469, dated Jun. 30, 2016 through May 22, 2017, 36 pp. |
Decision to Grant from counterpart European Application No. 04781529.5, dated Oct. 27, 2011, 2 pp. |
Number | Date | Country | |
---|---|---|---|
20170354804 A1 | Dec 2017 | US |
Number | Date | Country | |
---|---|---|---|
60499207 | Aug 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14562469 | Dec 2014 | US |
Child | 15633165 | US | |
Parent | 13766601 | Feb 2013 | US |
Child | 14562469 | US | |
Parent | 11823521 | Jun 2007 | US |
Child | 13766601 | US | |
Parent | 10773121 | Feb 2004 | US |
Child | 11823521 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10718038 | Nov 2003 | US |
Child | 10773121 | US |